GlassScriptPhysician profile
Aamir Zaman
NPI 1659542702
$3,844.86
in general payments reported to CMS, 2019-2025
58 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.51 · 2020: $82.45 · 2021: $96.10 · 2022: $965 · 2023: $1,014 · 2024: $739 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,374.37 |
| Education | $279.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $481.20 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $401.23 | 2022-2025 | Erleada, Tecvayli, Darzalex |
| Medtronic, INC. | $180.11 | 2022 | |
| Incyte Corporation | $146.84 | 2022-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $139.08 | 2020-2025 | Opdivo, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $138.95 | 2022-2025 | |
| Astellas Pharma US INC | $135.08 | 2022-2025 | Xtandi, Padcev, Xospata |
| Glaxosmithkline, LLC. | $129.50 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Intuitive Surgical, INC. | $128.75 | 2025 | |
| Daiichi Sankyo INC. | $121.89 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Merck Sharp & Dohme LLC | $108.47 | 2022-2024 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $106.15 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $81.67 | 2022-2025 | Monoferric, Cosela |
| Celgene Corporation | $80.07 | 2020-2023 | Reblozyl |
| Blueprint Medicines Corporation | $72.19 | 2022-2025 | Ayvakit |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $70.64 | 2019-2025 | Tecentriq |
| Seagen INC. | $60.90 | 2022-2023 | Tukysa, Padcev |
| Lilly USA, LLC | $58.80 | 2019-2024 | Jaypirca |
| Abbvie INC. | $58.34 | 2022-2025 | Venclexta |
| Amgen INC. | $56.48 | 2021-2023 | Lumakras |
| Gilead Sciences, INC. | $54.29 | 2021-2024 | Trodelvy |
| Pfizer INC. | $52.82 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $52.49 | 2023-2025 | Onivyde, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $50.96 | 2022 | |
| Dendreon Pharmaceuticals LLC | $49.42 | 2023-2024 | Provenge |
| Servier Pharmaceuticals LLC | $48.48 | 2022 | |
| Mirati Therapeutics, INC. | $47.42 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $42.86 | 2022-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $38.24 | 2020-2024 | Alunbrig |
| Genzyme Corporation | $36.32 | 2022-2025 | |
| Stemline Therapeutics INC. | $34.69 | 2024-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $34.48 | 2024-2025 | |
| Kite Pharma, INC. | $34.40 | 2020-2022 | |
| Adaptive Biotechnologies Corporation | $34.12 | 2024 | Clonoseq |
| Eisai INC. | $31.15 | 2022-2023 | |
| Emd Serono, INC. | $29.08 | 2022-2023 | Bavencio |
| Sumitomo Pharma America, INC. | $28.56 | 2023 | Orgovyx |
| Janssen Scientific Affairs, LLC | $27.10 | 2023 | Erleada |
| Emmaus Medical, INC. | $26.66 | 2023 | Endari |
| Myriad Genetic Laboratories, INC. | $23.16 | 2025 | Precisetumor |
| Apellis Pharmaceuticals, INC. | $21.99 | 2024 | Empaveli |
| Genmab U.S., INC. | $21.69 | 2025 | Epkinly |
| Beigene USA, INC. | $21.19 | 2024 | Brukinsa |
| Secura Bio, INC. | $19.91 | 2022 | |
| Puma Biotechnology, INC. | $18.97 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18.58 | 2025 | Qinlock, Romvimza |
| Rigel Pharmaceuticals, INC. | $18.37 | 2022 | |
| Pharmaessentia USA Corporation | $18.21 | 2025 | Besremi |
| Telix Pharmaceuticals | $17.49 | 2025 | Illuccix |
| Azurity Pharmaceuticals, INC. | $17.48 | 2024 | Vivimusta |
| Octapharma USA, INC. | $16.67 | 2024 | Octagam Immune Globulin (Human) |
| Myovant Sciences INC. | $16.44 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.95 | 2022 | |
| Cti Biopharma Corp. | $14.61 | 2023 | Vonjo |
| Alnylam Pharmaceuticals INC. | $14.29 | 2024 | Givlaari |
| Foundation Medicine, INC. | $14.22 | 2022 | |
| Caris Mpi, INC. | $13.91 | 2025 | Mi Cancer Seek |
| Novocure INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamir Zaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.